• Vitura executes $5.1 million share subscription agreement with AFO Investments
• Professor Khalil (Charlie) Shahin AO, a prominent Australian businessman, becomes a major shareholder
• Placement funds to be used for the $4 million acquisition of Candor Medical and future expansion plans

Vitura Health Limited (ASX: VIT), a leading digital health platform business, has executed a Share Subscription Agreement with AFO Investments Pty Ltd, as Trustee for the AFO Investment Trust (AFO), an entity associated with South Australian based high-net-worth investor Professor Khalil (Charlie) Shahin AO, to invest $5,171,196 in Vitura (Placement). Professor Shahin is the Managing Director of Peregrine Corporation, one of Australia's largest privately owned companies. The Company has issued a total of 74,814,757 ordinary shares to AFO at a price of $0.06912 per share, representing 11.4% of the Company's total issued capital. The placement funds will be used by the Company to fund the $4 million initial cash component associated with the purchase of Candor Medical, as announced by the Company on 12 February 2025, with the remainder to fund the Company's future expansion plans. Vitura Chair, Robert Iervasi, said 'Vitura is very pleased to be welcoming an experienced and proven business leader like Charlie Shahin as a substantial shareholder in the Company. As a major shareholder of the Company, Charlie will bring to Vitura a wealth of experience. Charlie's investment is an important validation of the potential of Vitura and our Strategy Reset, and the importance of providing patients with options in how they access healthcare in Australia.' Professor Shahin said 'I am delighted in becoming a major shareholder in Vitura. The business is well positioned for growth and I look forward to supporting Vitura in its growth platforms.'

The Company is confident that the acquisition of Candor Medical will deliver a material increase in Vitura's revenues and EBITDA in FY2025 and beyond.

The anticipated increase in EBITDA resulting from the acquisition of Candor will deliver a significant increase in earnings per share for the Company post the placement of shares to AFO.